Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2025)
Keros Therapeutics (KROS) reported Other Non Operating Income of $273000.0 for Q4 2025, up 219.21% on a YoY basis from $85522.6 in Q4 2024, and up 207.91% quarter-over-quarter from -$253000.0 in Q3 2025.
Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported Other Non Operating Income for 7 years, with the latest figure at $273000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income rose 219.21% year-over-year to $273000.0; the trailing twelve-month figure through Dec 2025 stood at -$539000.0 (up 43.5% YoY), and the FY2025 full-year result was -$539000.0, up 43.5% from the prior year.
- Other Non Operating Income for Q4 2025 stood at $273000.0, up from -$253000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $762000.0 in Q3 2022, with the low at -$1.4 million in Q4 2022.
- Historically, Other Non Operating Income has averaged -$134750.0 across 5 years, with a median of -$96500.0 in 2021.
- The largest YoY upside for Other Non Operating Income was 656.2% in 2022 against a maximum downside of 1288.12% in 2022.
- Keros Therapeutics' Other Non Operating Income stood at -$101000.0 in 2021, then slumped by 1288.12% to -$1.4 million in 2022, then jumped by 103.99% to $56000.0 in 2023, then sank by 508.93% to -$229000.0 in 2024, then jumped by 219.21% to $273000.0 in 2025.
- The last three Other Non Operating Income figures came in at $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and -$221000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 273,000.00 |
| Sep 30, 2025 | -253,000.00 |
| Jun 30, 2025 | -221,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -229,000.00 |
| Sep 30, 2024 | -92,000.00 |
| Jun 30, 2024 | -196,000.00 |
| Mar 31, 2024 | -437,000.00 |
| Dec 31, 2023 | 56,000.00 |
| Sep 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -155,000.00 |
| Mar 31, 2023 | -40,000.00 |
| Dec 31, 2022 | -1.40 Mn |
| Sep 30, 2022 | 762,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | -59,000.00 |
| Dec 31, 2021 | -101,000.00 |
| Sep 30, 2021 | -137,000.00 |
| Jun 30, 2021 | -80,000.00 |
| Mar 31, 2021 | -65,000.00 |